IMMP Immutep

Immutep to Present at Healthcare Investor Conferences

Immutep to Present at Healthcare Investor Conferences

Sydney, AUSTRALIA, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, will present at investor conferences, as outlined below.

2021 Cantor Fitzgerald Virtual Global Healthcare Conference

Participants: Marc Voigt, CEO will present a corporate overview in the virtual event format

Time/date:    Wednesday 29 September 2021, EDT (Eastern Daylight Time)

Information:  

Goldman Sachs Small/Mid-Cap Healthcare Day (virtual)

Presenter:   An informal discussion with Marc Voigt, CEO led by Goldman Sachs host Chris Cooper, Healthcare Analyst Global Investment Research and with investor Q&A.

Date:            Thursday 7 October 2021, AEST (Australian Eastern Standard Time)

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website or by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS

+61 (0)406 759 268;

U.S. Media:

Tim McCarthy, LifeSci Advisors

+1 (212) 915.2564; 



EN
28/09/2021

Underlying

IMMPImmutep

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immutep

 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase...

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's targeted enrolment Futility analysis and completion of patient enrolment remain on track for the first quarter and the third quarter of CY2026, respectively SYDNEY, AUSTRALIA, Feb. 06, 2026 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces...

February 6, 2026 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Quarterly Activities Report Q2 FY26

Immutep Quarterly Activities Report Q2 FY26 Media Release Entered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all countries outside North America, Europe, Japan, and Greater ChinaIn January 2026, Immutep received ~A$30 million upfront payment from Dr. Reddy’s and is eligible to receive up to ~A$528 million in potential milestones, plus royalties on commercial sales of eftiStrong operational progress reported for TACTI-004 (KEYNOTE-F91) Phase III trial evaluating efti in first line non-small cell lung cancer (1L NSCLC), with completion o...

January 29, 2026 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Ag...

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levelsDose dependent immunosuppressive effect against a strong foreign antigen observed with continued favourable safety profileSubstantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseasesGiven encouraging efficacy and safety, the trial will continue as planned and further updates are anticipated in 1H CY2026 including present...

December 22, 2025 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Announces Strong Operational Progress in Global TACTI-004 (KEY...

Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial’s targeted enrolmentStrong operational progress continues globally with over 120 activated clinical sites and 27 countries having received full regulatory approvals including the United States Futility analysis remains on track for the first quarter of CY2026 and completion of patient enrolment in the third quarter of CY2026 SYDNEY, AUSTRALIA, Dec. 16, 2025 (GLOBE ...

December 16, 2025 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commer...

Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa Dr. Reddy’s receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront payment of USD 20 million (~AUD 30.2 million) and is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million (~AUD 528.4 million), plus double-digit royalties on commercial sales Sydney, Australia/Hyd...

December 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch